BioStem Technologies (OTCMKTS:BSEM) Posts Earnings Results, Beats Estimates By $0.01 EPS

BioStem Technologies (OTCMKTS:BSEM) posted its quarterly earnings results on Tuesday. The company reported 0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of 0.31 by 0.01, Zacks reports. The company had revenue of 82.56 million during the quarter, compared to analysts’ expectations of 78.22 million.

BioStem Technologies Price Performance

BSEM traded down 1.63 during midday trading on Thursday, hitting 23.36. 115,357 shares of the company’s stock traded hands, compared to its average volume of 32,583. BioStem Technologies has a one year low of 2.34 and a one year high of 28.26. The stock’s fifty day simple moving average is 13.28 and its 200-day simple moving average is 10.64. The company has a market cap of $388.16 million, a PE ratio of 34.35 and a beta of -0.36.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.